Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein (original) (raw)

References

1. Dalton, WS & Jove, R Drug resistance in multiple myeloma: approaches to circumvention. Semin Oncol, (1999). 26 (5 Suppl. 13), 23–27.
   CAS PubMed Google Scholar
2. Epstein, J, Xiao, HQ & Oba, BK P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood, (1989). 74, 913–917.
   CAS PubMed Google Scholar
3. Sonneveld, P, Durie, BG, Lokhorst, HM, Marie, JP, Solbu, G, Suciu, S, Zittoun, R, Lowenberg, B & Nooter, K Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet, (1992). 340, 255–259.
   Article CAS PubMed Google Scholar
4. Grogan, TM, Spier, CM, Salmon, SE, Matzner, M, Rybski, J, Weinstein, RS, Scheper, RJ & Dalton, WS P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood, (1993). 81, 490–495.
   CAS PubMed Google Scholar
5. Raaijmakers, HG, Izquierdo, MA, Lokhorst, HM, de Leeuw, C, Belien, JA, Bloem, AC, Dekker, AW, Scheper, RJ & Sonneveld, P Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood, (1998). 91, 1029–1036.
   CAS PubMed Google Scholar
6. Filipits, M, Drach, J, Pohl, G, Schuster, J, Stranzl, T, Ackermann, J, Konigsberg, R, Kaufmann, H, Gisslinger, H, Huber, H, Ludwig, H & Pirker, R Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res, (1999). 5, 2426–2430.
   CAS PubMed Google Scholar
7. Linsenmeyer, ME, Jefferson, S, Wolf, M, Matthews, JP, Board, PG & Woodcock, DM Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer, (1992). 65, 471–475.
   Article CAS PubMed PubMed Central Google Scholar
8. Moalli, PA, Pillay, S, Weiner, D, Leikin, R & Rosen, ST A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood, (1992). 79, 213–222.
   CAS PubMed Google Scholar
9. Ishikawa, H, Kawano, MM, Okada, K, Tanaka, H, Tanabe, O, Sakai, A, Asaoku, H, Iwato, K, Nobuyoshi, M & Kuramoto, A Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells. Br J Haematol, (1993). 83, 68–74.
   Article CAS PubMed Google Scholar
10. Krett, NL, Pillay, S, Moalli, PA, Greipp, PR & Rosen, ST A variant glucocorticoid receptor messenger RNA is expressed in multiple myeloma patients. Cancer Res, (1995). 55, 2727–2729.
    CAS PubMed Google Scholar
11. Futscher, BW, Foley, NE, Gleason-Guzman, MC, Meltzer, PS, Sullivan, DM & Dalton, WS Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer, (1996). 66, 520–525.
    Article CAS PubMed Google Scholar
12. Solary, E, Droin, N, Bettaieb, A, Corcos, L, Dimanche-Boitrel, MT & Garrido, C Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia, (2000). 14, 1833–1849.
    Article CAS PubMed Google Scholar
13. O’Gorman, DM & Cotter, TG Molecular signals in anti-apoptotic survival pathways. Leukemia, (2001). 15, 21–34.
    Article PubMed Google Scholar
14. Hardin, J, MacLeod, S, Grigorieva, I, Chang, R, Barlogie, B, Xiao, H & Epstein, J Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood, (1994). 84, 3063–3070.
    CAS PubMed Google Scholar
15. Lichtenstein, A, Tu, Y, Fady, C, Vescio, R & Berenson, J Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol, (1995). 162, 248–255.
    Article CAS PubMed Google Scholar
16. Rowley, M, Liu, P & Van Ness, B Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood, (2000). 96, 3175–3180.
    CAS PubMed Google Scholar
17. Neri, A, Murphy, JP, Cro, L, Ferrero, D, Tarella, C, Baldini, L & Dalla-Favera, R Ras oncogene mutation in multiple myeloma. J Exp Med, (1989). 170, 1715–1725.
    Article CAS PubMed Google Scholar
18. Billadeau, D, Liu, P, Jelinek, D, Shah, N, LeBien, TW & Van Ness, B Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res, (1997). 57, 2268–2275.
    CAS PubMed Google Scholar
19. Grigorieva, I, Thomas, X & Epstein, J The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol, (1998). 26, 597–603.
    CAS PubMed Google Scholar
20. Cheung, WC & Van Ness, B The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia, (2001). 15, 264–271.
    Article CAS PubMed Google Scholar
21. Damiano, JS, Cress, AE, Hazlehurst, LA, Shtil, AA & Dalton, WS Cell adhesion mediated drug resistance (CAM-DR: role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, (1999). 93, 1658–1667.
    CAS PubMed Google Scholar
22. Gauthier, ER, Piche, L, Lemieux, G & Lemieux, R Role of bcl-X(L)in the control of apoptosis in murine myeloma cells. Cancer Res, (1996). 56, 1451–1456.
    CAS PubMed Google Scholar
23. Tu, Y, Renner, S, Xu, F, Fleishman, A, Taylor, J, Weisz, J, Vescio, R, Rettig, M, Berenson, J, Krajewski, S, Reed, JC & Lichtenstein, A BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res, (1998). 58, 256–262.
    CAS PubMed Google Scholar
24. Zhang, B, Gojo, I & Fenton, RG Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood, (2002). 99, 1885–1893.
    Article CAS PubMed Google Scholar
25. Derenne, S, Monia, B, Dean, NM, Taylor, JK, Rapp, MJ, Harousseau, JL, Bataille, R & Amiot, M Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood, (2002). 100, 194–199.
    Article CAS PubMed Google Scholar
26. Tu, Y, Xu, FH, Liu, J, Vescio, R, Berenson, J, Fady, C & Lichtenstein, A Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood, (1996). 88, 1805–1812.
    CAS PubMed Google Scholar
27. Gazitt, Y, Fey, V, Thomas, C & Alvarez, R Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol, (1998). 13, 397–405.
    CAS PubMed Google Scholar
28. Hamilton, MS, Barker, HF, Ball, J, Drew, M, Abbot, SD & Franklin, IM Normal and neoplastic human plasma cells express bcl-2 antigen. Leukemia, (1991). 5, 768–771.
    CAS PubMed Google Scholar
29. Pettersson, M, Jernberg-Wiklund, H, Larsson, LG, Sundstrom, C, Givol, I, Tsujimoto, Y & Nilsson, K Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood, (1992). 79, 495–502.
    CAS PubMed Google Scholar
30. Sangfelt, O, Osterborg, A, Grander, D, Anderbring, E, Ost, A, Mellstedt, H & Einhorn, S Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer, (1995). 63, 190–192.
    Article CAS PubMed Google Scholar
31. Ong, F, van Nieuwkoop, JA, Groot-Swings, GM, Hermans, J, Harvey, MS, Kluin, PM & Kluin-Nelemans, JC Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia, (1995). 9, 1282–1284.
    CAS PubMed Google Scholar
32. Harada, N, Hata, H, Yoshida, M, Soniki, T, Nagasaki, A, Kuribayashi, N, Kimura, T, Matsuzaki, H & Mitsuya, H Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia, (1998). 12, 1817–1820.
    Article CAS PubMed Google Scholar
33. Puthier, D, Pellat-Deceunynck, C, Barille, S, Robillard, N, Rapp, MJ, Juge-Morineau, N, Harousseau, JL, Bataille, R & Amiot, M Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia, (1999). 13, 289–294.
    Article CAS PubMed Google Scholar
34. Renner, S, Weisz, J, Krajewski, S, Krajewska, M, Reed, JC & Lichtenstein, A Expression of BAX in plasma cell dyscrasias. Clin Cancer Res, (2000). 6, 2371–2380.
    CAS PubMed Google Scholar
35. Gross, A, McDonnell, JM & Korsmeyer, SJ BCL-2 family members and the mitochondria in apoptosis. Genes Dev, (1999). 13, 1899–1911.
    Article CAS PubMed Google Scholar
36. Kroemer, G & Reed, JC Mitochondrial control of cell death. Nat Med, (2000). 6, 513–519.
    Article CAS PubMed Google Scholar
37. Schwarze, MM & Hawley, RG Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res, (1995). 55, 2262–2265.
    CAS PubMed Google Scholar
38. Gewirtz, AM, Sokol, DL & Ratajczak, MZ Nucleic acid therapeutics: state of the art and future prospects. Blood, (1998). 92, 712–736.
    CAS PubMed Google Scholar
39. Campos, L, Sabido, O, Rouault, JP & Guyotat, D Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood, (1994). 84, 595–600.
    CAS PubMed Google Scholar
40. Cotter, FE, Johnson, P, Hall, P, Pocock, C, al Mahdi, N, Cowell, JK & Morgan, G Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene, (1994). 9, 3049–3055.
    CAS PubMed Google Scholar
41. Pepper, C, Thomas, A, Hoy, T, Cotter, F & Bentley, P Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol, (1999). 107, 611–615.
    Article CAS PubMed Google Scholar
42. Miyake, H, Tolcher, A & Gleave, ME Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model. Cancer Res, (1999). 59, 4030–4034.
    CAS PubMed Google Scholar
43. Schlagbauer-Wadl, H, Klosner, G, Heere-Ress, E, Waltering, S, Moll, I, Wolff, K, Pehamberger, H & Jansen, B Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol, (2000). 114, 725–730.
    Article CAS PubMed Google Scholar
44. Guinness, ME, Kenney, JL, Reiss, M & Lacy, J Bcl-2 antisense oligodeoxynucleotide therapy of Epstein–Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Res, (2000). 60, 5354–5358.
    CAS PubMed Google Scholar
45. Tortora, G, Caputo, R, Damiano, V, Bianco, R, Fontanini, G, Cuccato, S, De Placido, S, Bianco, AR & Ciardiello, F Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Clin Cancer Res, (2001). 7, 2537–2544.
    CAS PubMed Google Scholar
46. Zangemeister-Wittke, U, Schenker, T, Luedke, GH & Stahel, RA Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer, (1998). 78, 1035–1042.
    Article CAS PubMed PubMed Central Google Scholar
47. Jansen, B, Schlagbauer-Wadl, H, Brown, BD, Bryan, RN, van Elsas, A, Muller, M, Wolff, K, Eichler, HG & Pehamberger, H bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med, (1998). 4, 232–234.
    Article CAS PubMed Google Scholar
48. Gleave, ME, Miayake, H, Goldie, J, Nelson, C & Tolcher, A Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology, (1999). 54 (6A Suppl.), 36–46.
    Article CAS PubMed Google Scholar
49. Konopleva, M, Tari, AM, Estrov, Z, Harris, D, Xie, Z, Zhao, S, Lopez-Berestein, G & Andreeff, M Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood, (2000). 95, 3929–3938.
    CAS PubMed Google Scholar
50. Klasa, RJ, Bally, MB, Ng, R, Goldie, JH, Gascoyne, RD & Wong, FM Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res, (2000). 6, 2492–2500.
    CAS PubMed Google Scholar
51. Lopes de Menezes, DE, Hudon, N, McIntosh, N & Mayer, LD Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res, (2000). 6, 2891–2902.
    CAS PubMed Google Scholar
52. Webb, A, Cunningham, D, Cotter, F, Clarke, PA, di Stefano, F, Ross, P, Corbo, M & Dziewanowska, Z BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, (1997). 349, 1137–1141.
    Article CAS PubMed Google Scholar
53. Waters, JS, Webb, A, Cunningham, D, Clarke, PA, Raynaud, F, di Stefano, F & Cotter, FE Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol, (2000). 18, 1812–1823.
    Article CAS PubMed Google Scholar
54. Jansen, B, Wacheck, V, Heere-Ress, E, Schlagbauer-Wadl, H, Hoeller, C, Lucas, T, Hoermann, M, Hollenstein, U, Wolff, K & Pehamberger, H Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet, (2000). 356, 1728–1733.
    Article CAS PubMed Google Scholar
55. Jego, G, Robillard, N, Puthier, D, Amiot, M, Accard, F, Pineau, D, Harousseau, JL, Bataille, R & Pellat-Deceunynck, C Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood, (1999). 94, 701–712.
    CAS PubMed Google Scholar
56. Haigler, HT, Maxfield, FR, Willingham, MC & Pastan, I Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J Biol Chem, (1980). 255, 1239–1241.
    CAS PubMed Google Scholar
57. Roovers, DJ, van Vliet, M, Bloem, AC & Lokhorst, HM Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res, (1999). 23, 539–548.
    Article CAS PubMed Google Scholar
58. van de Donk, NW, Kamphuis, MM, Lokhorst, HM & Bloem, AC The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia, (2002). 16, 1362–1371.
    Article CAS PubMed Google Scholar
59. Koziolkiewicz, M, Gendaszewska, E, Maszewska, M, Stein, CA & Stec, WJ The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5′-nucleotidase. Blood, (2001). 98, 995–1002.
    Article CAS PubMed Google Scholar
60. Ballas, ZK, Rasmussen, WL & Krieg, AM Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol, (1996). 157, 1840–1845.
    CAS PubMed Google Scholar
61. Yi, AK, Chang, M, Peckham, DW, Krieg, AM & Ashman, RF CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol, (1998). 160, 5898–5906.
    CAS PubMed Google Scholar
62. Stein, CA Does antisense exist?. Nat Med, (1995). 1, 1119–1121.
    Article CAS PubMed Google Scholar
63. Beltinger, C, Saragovi, HU, Smith, RM, LeSauteur, L, Shah, N, DeDionisio, L, Christensen, L, Raible, A, Jarett, L & Gewirtz, AM Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest, (1995). 95, 1814–1823.
    Article CAS PubMed PubMed Central Google Scholar
64. Durie, BG Staging and kinetics of multiple myeloma. Semin Oncol, (1986). 13, 300–309.
    CAS PubMed Google Scholar

Download references